Myeloma, Plasma-Cell
9
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
22.2%
2 terminated out of 9 trials
77.8%
-8.8% vs benchmark
0%
0 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (9)
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Phase I/II Study of hLL1 in Multiple Myeloma
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Multi-day Doses in Prevention of Nausea and Emesis
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood